Vir Biotechnology, Inc.
http://www.vir.bio
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vir Biotechnology, Inc.
Regeneron Targets Vulnerable Populations In COVID-19 Pact With BARDA
The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.
Several Options Remain For Cidara’s Flu Candidate After J&J Halts Development
Clinical work on the US biotech’s drug-Fc conjugate, CD388, has been stopped by partner Janssen amid a broader company shift, but there are several paths forward for Cidara after the asset showed early promise in a Phase IIa trial.
Vir’s VIR-2482 Flunks In Phase II As Company Shifts Focus To Other Programs
Negative results from the PENINSULA study cast doubt on a Phase Ib study of the antibody in elderly adults. The company unveiled its next-generation flu drug, VIR-2981.
Brii Ups Its Bet On VBI’s Hepatitis B Assets Amid Larger Treatment, Prevention Push
The two companies have partnered on VBI-2601 since 2018, and Brii is now taking global rights to that program as well as licensing rights to VBI’s hepatitis B vaccine.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Humabs BioMed SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice